Systolic blood pressure and six-year mortality in South Africa: Evidence from a country-wide population-based cohort study.
health policy
hypertension
longevity
mortality
primary care
sub-Saharan Africa
Journal
The lancet. Healthy longevity
ISSN: 2666-7568
Titre abrégé: Lancet Healthy Longev
Pays: England
ID NLM: 101773309
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
ppublish
Résumé
Improving hypertension control is an important global health priority yet, to our knowledge, there is no direct evidence on the blood pressure (BP)-mortality relationship in sub-Saharan Africa. We investigate the BP-mortality relationship in South Africa and assess the comparative effectiveness of different care targets for clinical care and population-wide hypertension management efforts. We use country-wide population-based longitudinal data from five waves (2008 - 2017) of the South African National Income Dynamics Study (N = 4,993). We estimate the relationship between systolic BP (SBP) and six-year all-cause mortality and compare the mortality reductions associated with lowering SBP to different targets. We then estimate the number needed to treat to avert one death (NNT) under different hypothetical population-wide scale up scenarios. We found a weak, nonlinear, SBP-mortality relationship with larger incremental mortality benefits at higher SBP values: reducing SBP from 160 to 150 mmHg was associated with a mortality risk ratio of 0.95 (95% CI: 0.90, 0.99, p = 0.033), incrementally reducing SBP from 150 to 140 mmHg a risk ratio of 0.96 (95% CI: 0.91, 1.01, p = 0.12), with no evidence of incremental benefits of reducing BP below 140 mmHg. At the population level, reducing SBP to 150 mmHg among all those with an SBP > 150 mmHg had the lowest NNT (50) at 3.3 deaths averted (95% CI: -0.6, 0.3) per 1,000 population while requiring BP management for 16% (95% CI: 15.2, 17.3) of individuals. The SBP-mortality association is weaker in South Africa than in high-income and many low- and middle-income countries. As such, we do not find compelling evidence in support of targets below 140 mmHg and find that scaling up management based on a 150 mmHg target is more efficient in terms of the NNT compared to strategies to reduce SBP to lower values.
Sections du résumé
Background
Improving hypertension control is an important global health priority yet, to our knowledge, there is no direct evidence on the blood pressure (BP)-mortality relationship in sub-Saharan Africa. We investigate the BP-mortality relationship in South Africa and assess the comparative effectiveness of different care targets for clinical care and population-wide hypertension management efforts.
Methods
We use country-wide population-based longitudinal data from five waves (2008 - 2017) of the South African National Income Dynamics Study (N = 4,993). We estimate the relationship between systolic BP (SBP) and six-year all-cause mortality and compare the mortality reductions associated with lowering SBP to different targets. We then estimate the number needed to treat to avert one death (NNT) under different hypothetical population-wide scale up scenarios.
Findings
We found a weak, nonlinear, SBP-mortality relationship with larger incremental mortality benefits at higher SBP values: reducing SBP from 160 to 150 mmHg was associated with a mortality risk ratio of 0.95 (95% CI: 0.90, 0.99, p = 0.033), incrementally reducing SBP from 150 to 140 mmHg a risk ratio of 0.96 (95% CI: 0.91, 1.01, p = 0.12), with no evidence of incremental benefits of reducing BP below 140 mmHg. At the population level, reducing SBP to 150 mmHg among all those with an SBP > 150 mmHg had the lowest NNT (50) at 3.3 deaths averted (95% CI: -0.6, 0.3) per 1,000 population while requiring BP management for 16% (95% CI: 15.2, 17.3) of individuals.
Interpretation
The SBP-mortality association is weaker in South Africa than in high-income and many low- and middle-income countries. As such, we do not find compelling evidence in support of targets below 140 mmHg and find that scaling up management based on a 150 mmHg target is more efficient in terms of the NNT compared to strategies to reduce SBP to lower values.
Identifiants
pubmed: 35309286
doi: 10.1016/s2666-7568(20)30050-7
pmc: PMC8932102
mid: NIHMS1762643
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e78-e86Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Epidemiology. 2020 May;31(3):393-401
pubmed: 32267655
Stat Med. 2019 May 10;38(10):1855-1868
pubmed: 30575102
BMJ. 2009 May 19;338:b1665
pubmed: 19454737
Hypertension. 2020 Jan;75(1):16-22
pubmed: 31735086
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Epidemiology. 2019 May;30(3):388-395
pubmed: 30789426
Lancet Glob Health. 2018 Nov;6(11):e1153-e1154
pubmed: 30196092
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Tydskr Stud Ekon Ekon. 2010 Jan 1;34(3):69-85
pubmed: 21915159
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Lancet Glob Health. 2018 Jul;6(7):e787-e794
pubmed: 29903379
BMJ Glob Health. 2017 Aug 16;2(3):e000348
pubmed: 29082013
PLoS One. 2018 Aug 1;13(8):e0200606
pubmed: 30067758
J Hypertens. 2019 Jan;37(1):24-29
pubmed: 30499921
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Am J Epidemiol. 2017 Jul 15;186(2):131-142
pubmed: 28838064
Cardiovasc J Afr. 2019 May/Jun 23;30(3):184-187
pubmed: 31140549
Cardiovasc J Afr. 2014 Nov-Dec;25(6):288-94
pubmed: 25629715
Lancet Glob Health. 2019 Feb;7(2):e270-e280
pubmed: 30528531
Int J Epidemiol. 2019 Jun 1;48(3):954-965
pubmed: 30428051
Am J Hypertens. 1999 Feb;12(2 Pt 2):43S-49S
pubmed: 10090294
Am Fam Physician. 2017 Oct 1;96(7):453-461
pubmed: 29094913
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272